Takeda (TAK) Q4 2025 earnings review
Surviving the Patent Cliff, but the Growth Transition Will Cost You
Takeda has officially weathered the worst of the VYVANSE generic cliff. Full-year FY25 revenue fell 1.7% to JPY 4,505.7 billion, largely dragged down by a 26.8% collapse in the Neuroscience segment. However, management executed a masterclass in cost discipline: Core Operating Profit actually grew 0.8% and margins expanded to 26.0%, defying the top-line contraction. The narrative is now aggressively pivoting to a 'new business cycle' fueled by three pivotal late-stage pipeline readouts (oveporexton, rusfertide, zasocitinib) and a transformative $1.2B oncology partnership with Innovent. But investors must pay the toll for this transition: FY26 guidance indicates that while revenue growth is Reversing to positive (+3.0%), earnings are Decelerating sharply. Core EPS is guided down 8.7% as management unleashes a massive JPY 170 billion in restructuring costs and aggressively reinvests into R&D to fund upcoming launches.
🐂 Bull Case
The massive JPY ~150 billion revenue crater left by VYVANSE generics is now largely in the rearview mirror. With that anchor removed, the underlying 'Growth and Launch' product portfolio is poised to drive the top line higher in FY26.
Takeda achieved a Core Operating Margin of 26.0% (up from 25.4% last year) despite losing its highest-margin neuroscience sales. Their enterprise-wide efficiency program is successfully shielding the bottom line.
🐻 Bear Case
The pivot to growth is expensive. A ballooning restructuring bill (up to JPY 170 billion in FY26) and heavy pre-launch R&D investments will cause Core Operating Profit to fall 1.1% despite higher revenue.
The crown jewel, ENTYVIO, saw growth decelerate to just 4.8%. It faces severe access hurdles for its subcutaneous PEN formulation in the U.S., intensifying competition in Crohn's Disease, and looming IRA price negotiations.
⚖️ Verdict: ⚪
Neutral. Takeda deserves credit for preserving margins through a brutal patent cliff. However, the steep guided decline in FY26 earnings and the high execution risk of simultaneously launching three major pipeline assets keep us on the sidelines for now.
Key Themes
Profitability Squeezed by Restructuring and Reinvestment
The most glaring contradiction in the report is the FY26 guidance: revenue is Reversing to positive growth, but Core EPS is Decelerating by 8.7%. This disconnect is driven by a massive spike in restructuring expenses (from JPY 70.8 billion to JPY 170.0 billion) tied to the company's transformation program, alongside a JPY 86.1 billion jump in R&D expenses to fund Phase 3 trials for zasocitinib, elritercept, and the newly acquired Innovent assets. Takeda is essentially sacrificing a year of earnings to fund its future.
Macro Headwinds: U.S. Medicare Redesign and IRA Negotiations
Takeda is bracing for substantial U.S. policy impacts. The Medicare Part D redesign and 340B program expansion already created significant gross-to-net rebate headwinds in FY25. More concerning is that ENTYVIO was selected for the third cycle of IRA price negotiations, which will likely result in a substantial Medicare price cut from 2028. Management noted they are preparing for these talks, but the financial impact remains a looming black box.
ENTYVIO Growth Hits a Wall
Decelerating. ENTYVIO revenue grew 4.8% to JPY 958.0 billion, a notable slowdown. The much-anticipated ENTYVIO PEN is facing slower-than-expected adoption in the U.S. due to reimbursement and market access hurdles. While management points to ~30% quarter-over-quarter patient growth for the PEN, the top-line deceleration contradicts the broader narrative of unstoppable momentum in the 'Growth and Launch' portfolio.
The Orexin Franchise (oveporexton)
Accelerating. The pipeline's brightest star is oveporexton, which delivered 'outstanding' Phase 3 results in narcolepsy type 1, meeting all primary and secondary endpoints. Takeda views this as a multi-billion dollar opportunity that will establish a new standard of care. With a U.S. filing imminent, the company is also advancing TAK-360 into Phase 2, explicitly stating their intention to 'win and own this pathway.'
Transformative Oncology Expansion via Innovent
Takeda made a massive JPY 184.7 billion ($1.2B) upfront bet on two late-stage oncology assets from Innovent Biologics: IBI363 (a PD-1/IL-2 bispecific) and IBI343 (a Claudin 18.2 ADC). Targeting heavily pre-treated solid tumors (lung, CRC, gastric), this addresses an initial market opportunity exceeding $40 billion. While it adds severe near-term R&D burden, it radically upgrades Takeda's post-2030 growth profile.
Neuroscience Collapse Skews the Top Line
Reversing. The Neuroscience segment collapsed 26.8% to JPY 414.3 billion, almost entirely due to a 42.0% drop in VYVANSE/ELVANSE (JPY 203.2 billion) following generic entry in the U.S. The critical takeaway: management confirmed that FY25 was the peak of this erosion, meaning the segment drag will significantly diminish in FY26.
Other KPIs
Stable/Accelerating. Improved from 25.4% in FY24. This is a remarkable achievement given the loss of high-margin VYVANSE revenue. It proves that the enterprise-wide efficiency program (targeting JPY 200B+ in annualized gross savings) is functioning exactly as intended, stripping out SG&A and R&D fat to protect the bottom line.
Decelerating. Down 11.0% from JPY 769.0 billion in FY24, but this includes the massive $1.2 billion upfront payment for the Innovent oncology assets. Excluding that strategic M&A outlay, underlying cash generation remains exceptionally strong, supporting the decision to increase the dividend to 200 JPY/share for FY25 and guide for 204 JPY/share in FY26.
Stable. Improved from 2.8x in FY24. The company maintains a JPY 250 billion equity credit for its hybrid subordinated bonds. The steady deleveraging profile limits financial risk as Takeda enters a heavy reinvestment cycle.
Guidance
Reversing. Guides for a 3.0% increase, flipping the script from the 1.7% decline in FY25. Growth will be driven by continued momentum in PDT and new product launches, finally outpacing the residual VYVANSE drag.
Decelerating. Represents a 1.1% decline. The divergence between top-line growth and bottom-line contraction is entirely due to deliberate R&D reinvestment into late-stage pipeline assets and aggressive restructuring costs.
Reversing. Down 8.7% from 517 JPY in FY25. The steep drop is exacerbated by a normalized expected tax rate of 'low 10s%', compared to the artificially low ~12% tax rate in FY25 that benefited from a deferred tax asset reassessment.
Stable. Despite the projected drop in Core EPS, cash generation remains resilient, bolstered by a significant reduction in capital expenditures (down from JPY 410.9 billion to JPY 330.0-380.0 billion), as FY25 included the heavy upfront Innovent payment.
Key Questions
Innovent R&D Burn Rate
You've highlighted a $40B+ TAM for IBI363 and plan up to five Phase 3 trials. How much incremental R&D expense is baked into the FY26 guidance specifically for these massive solid tumor studies, and does this alter the timeline for reaching your low-30s% margin target?
The Floor for ENTYVIO
With ENTYVIO PEN facing access hurdles and IRA price negotiations approaching, at what point does the current 4.8% growth rate turn negative? Are you still confident in the previously stated peak sales guidance?
Oveporexton Commercial Ramp
You noted that diagnosing Narcolepsy Type 1 through sleep centers is a significant bottleneck. How much incremental SG&A are you allocating in FY26 to unblock these diagnostic pathways ahead of the oveporexton launch?
Restructuring Expenses
Other operating expenses are ballooning to JPY 229 billion in FY26, heavily driven by JPY 170 billion in restructuring costs. Can you detail exactly what these restructuring costs cover and when we can expect them to fully normalize?